TITLE

FDA Safety Page

AUTHOR(S)
Holquist, Carol
PUB. DATE
January 2002
SOURCE
Patient Care;1/15/2002, Vol. 36 Issue 1, p54
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Focuses on the drug name review process created by the U.S. Food and Drug Administration in January 2002. Handwriting and verbal analyses; Computer assisted analysis; Evaluation of risks.
ACCESSION #
6115438

 

Related Articles

  • FDA Approved 90 New Original Drugs in 1998. SWEENEY, ROSEMARIE; ROSE, VERNA L. // American Family Physician;3/1/1999, Vol. 59 Issue 5, p1095 

    Deals with the ninety new drugs approved by the United States Food and Drug Administration (FDA) in 1998. Median approval time for the drugs; Biologic products approved by FDA; Brief background on the drugs.

  • Paranoid annoyance. Schwartz, Harry // Pharmaceutical Executive;Sep98, Vol. 18 Issue 9, p24 

    Focuses on the withdrawal of several pharmaceutical products in the United States market due to their adverse effects on human body. Political aspects of the problem; Reason behind Food and Administration's (FDA) approval of propulsid and sildenafil; Possible effects of the move of FDA.

  • New molecular entities.  // Formulary;Sep97, Vol. 32 Issue 9, p881 

    Presents several drugs approved by the US Food and Drug Administration. Sodium capsules for the management of pain; Tablets for the treatment of advanced breast cancer; Dopamine agonist for the treatment of Parkinson's disease.

  • Ban the Bromate.  // Nutrition Action Health Letter;Oct99, Vol. 26 Issue 8, p2 

    Focuses on the efforts of the United States Food and Drug Administration to ban bromate in baked goods. Adverse effects of potassium bromate; Brands that still use potassium bromate.

  • Bill seeks to bring FDA's blurry lines into focus. Wechsler, Jill // Managed Healthcare;Dec97, Vol. 7 Issue 12, p22 

    Focuses on the legislation that clarifies the United States Food and Drug Administration regulations. Allowing of pharmaceutical companies to disseminate competent healthcare economic information to sophisticated purchasers; Allowing of drugmakers to distribute peer-reviewed journal articles...

  • FDA issues reprint guidelines.  // Dermatology Times;Jan1996, Vol. 17 Issue 1, p68 

    Reports that the Food and Drug Administration will be issuing guidelines, permitting distribution of journal reprints studies, that support an approved indication, but make reference to unapproved uses. What companies will be allowed to distribute; Guidelines concerning IND submission.

  • Consumer groups blast FDA reform legislation.  // Health Facilities Management;Sep97, Vol. 10 Issue 9, p10 

    Focuses on the legislation aimed at reforming the US Food and Drug Administration, led by retired Senator Howard Metzenbaum. Bill that was approved by the Senate Labor and Human Resources Committee; One of the provisions that is troubling Metzenbaum.

  • Close call. Conlan, Michael F. // Drug Topics;12/8/97, Vol. 141 Issue 23, p101 

    Looks at United States Food and Drug Administration (FDA), reform on the protection legislation for pharmacies, with reference to House and Senate conferees. Limits of the FDA authority; Importance of federal law; Information FDA reform package.

  • More changes & challenges at FDA. Wechsler, Jill // Pharmaceutical Executive;Feb98, Vol. 18 Issue 2, p24 

    Reports on changes, challenges and issues arising from efforts to implement policies required by the enacted US Food and Drug Administration Modernization Act. Improvement in quality and processing of drug marketing applications; Increase of new-drug and product applications; Comments on the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics